Literature DB >> 26783074

Too much of a good thing: Sustained type 1 interferon signaling limits humoral responses to secondary viral infection.

John R Teijaro1,2.   

Abstract

The induction of a pan-immunosuppressive state is a central feature of persistent viral infections. Over the past decade, multiple pathways have been identified that contribute to immune suppression. Recently, it was revealed that aberrant or sustained type 1 interferon (IFN-I) production or signaling is a central contributor to immune suppression elicited during persistent viral infection. In this issue, Honke et al. [Eur. J. Immunol. 2016. 46: 372-380] identify that IFN-I signaling promotes an immune suppressive state during persistent lymphocytic choriomeningitis virus infection by inhibiting enforced virus replication in CD169(+) macrophages. The authors demonstrate that mice infected with a persistent strain of lymphocytic choriomeningitis virus have blunted humoral immune responses to a superinfecting vesicular stomatitis virus infection. The absence of virus replication in CD169(+) macrophages was not due to antiviral CD8(+) T cell-mediated killing of CD169(+) macrophages, but required sustained IFN-I responses. In turn, reduction in vesicular stomatitis virus replication in CD169(+) macrophages resulted in a reduction in antigen production, which is necessary for generating optimal humoral responses. This study highlights a novel mechanism by which IFN-I signaling promotes an immune suppressive state during persistent viral infection.
© 2016 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.

Entities:  

Keywords:  Chronic infection; Lymphocytic choriomeningitis virus; Macrophages; Type I Interferon; Vesicular stomatitis virus

Mesh:

Substances:

Year:  2016        PMID: 26783074      PMCID: PMC5113021          DOI: 10.1002/eji.201546224

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  12 in total

Review 1.  General and specific immunosuppression caused by antiviral T-cell responses.

Authors:  R M Zinkernagel; O Planz; S Ehl; M Battegay; B Odermatt; P Klenerman; H Hengartner
Journal:  Immunol Rev       Date:  1999-04       Impact factor: 12.988

2.  Enforced viral replication activates adaptive immunity and is essential for the control of a cytopathic virus.

Authors:  Nadine Honke; Namir Shaabani; Giuseppe Cadeddu; Ursula R Sorg; Dong-Er Zhang; Mirko Trilling; Karin Klingel; Martina Sauter; Reinhard Kandolf; Nicole Gailus; Nico van Rooijen; Christoph Burkart; Stephan E Baldus; Melanie Grusdat; Max Löhning; Hartmut Hengel; Klaus Pfeffer; Masato Tanaka; Dieter Häussinger; Mike Recher; Philipp A Lang; Karl S Lang
Journal:  Nat Immunol       Date:  2011-11-20       Impact factor: 25.606

3.  Interleukin-10 determines viral clearance or persistence in vivo.

Authors:  David G Brooks; Matthew J Trifilo; Kurt H Edelmann; Luc Teyton; Dorian B McGavern; Michael B A Oldstone
Journal:  Nat Med       Date:  2006-10-15       Impact factor: 53.440

4.  Infected CD8α- dendritic cells are the predominant source of IL-10 during establishment of persistent viral infection.

Authors:  Cherie T Ng; Michael B A Oldstone
Journal:  Proc Natl Acad Sci U S A       Date:  2012-08-14       Impact factor: 11.205

5.  Restoring function in exhausted CD8 T cells during chronic viral infection.

Authors:  Daniel L Barber; E John Wherry; David Masopust; Baogong Zhu; James P Allison; Arlene H Sharpe; Gordon J Freeman; Rafi Ahmed
Journal:  Nature       Date:  2005-12-28       Impact factor: 49.962

6.  Viral targeting of fibroblastic reticular cells contributes to immunosuppression and persistence during chronic infection.

Authors:  Scott N Mueller; Mehrdad Matloubian; Daniel M Clemens; Arlene H Sharpe; Gordon J Freeman; Shivaprakash Gangappa; Christian P Larsen; Rafi Ahmed
Journal:  Proc Natl Acad Sci U S A       Date:  2007-09-18       Impact factor: 11.205

7.  Blockade of chronic type I interferon signaling to control persistent LCMV infection.

Authors:  Elizabeth B Wilson; Douglas H Yamada; Heidi Elsaesser; Jonathan Herskovitz; Jane Deng; Genhong Cheng; Bruce J Aronow; Christopher L Karp; David G Brooks
Journal:  Science       Date:  2013-04-12       Impact factor: 47.728

8.  Persistent LCMV infection is controlled by blockade of type I interferon signaling.

Authors:  John R Teijaro; Cherie Ng; Andrew M Lee; Brian M Sullivan; Kathleen C F Sheehan; Megan Welch; Robert D Schreiber; Juan Carlos de la Torre; Michael B A Oldstone
Journal:  Science       Date:  2013-04-12       Impact factor: 47.728

9.  Virus-induced immunosuppression: immune system-mediated destruction of virus-infected dendritic cells results in generalized immune suppression.

Authors:  P Borrow; C F Evans; M B Oldstone
Journal:  J Virol       Date:  1995-02       Impact factor: 5.103

10.  Natural killer cells act as rheostats modulating antiviral T cells.

Authors:  Stephen N Waggoner; Markus Cornberg; Liisa K Selin; Raymond M Welsh
Journal:  Nature       Date:  2011-11-20       Impact factor: 49.962

View more
  4 in total

1.  Maf expression in human macrophages and lymph node sinus macrophages in patients with esophageal cancer.

Authors:  Hiroto Takeya; Koji Ohnishi; Takuya Shiota; Yoichi Saito; Yukio Fujiwara; Taisuke Yagi; Yuki Kiyozumi; Yoshifumi Baba; Naoya Yoshida; Kenichi Asano; Masato Tanaka; Hideo Baba; Yoshihiro Komohara
Journal:  J Clin Exp Hematop       Date:  2019

Review 2.  Type I interferon and HIV: Subtle balance between antiviral activity, immunopathogenesis and the microbiome.

Authors:  Carolina Scagnolari; Guido Antonelli
Journal:  Cytokine Growth Factor Rev       Date:  2018-03-16       Impact factor: 7.638

3.  CSF-1-induced DC-SIGN+ macrophages are present in the ovarian endometriosis.

Authors:  Li Xiaocui; Hong Wei; Cai Yunlang; Zheng Zhenzhen; An Min
Journal:  Reprod Biol Endocrinol       Date:  2022-03-08       Impact factor: 5.211

4.  USP18 is a significant driver of memory CD4 T-cell reduced viability caused by type I IFN signaling during primary HIV-1 infection.

Authors:  Xavier Dagenais-Lussier; Hamza Loucif; Hugo Cadorel; Juliette Blumberger; Stéphane Isnard; Mariana Gé Bego; Éric A Cohen; Jean-Pierre Routy; Julien van Grevenynghe
Journal:  PLoS Pathog       Date:  2019-10-28       Impact factor: 6.823

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.